Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay

Int J Tuberc Lung Dis. 2014 Feb;18(2):227-32. doi: 10.5588/ijtld.13.0229.

Abstract

Objective: To establish breakpoint concentrations for the fluoroquinolones (moxifloxacin [MFX] and ofloxacin [OFX]) and injectable second-line drugs (amikacin [AMK], kanamycin [KM] and capreomycin [CPM]) using the microscopic observation drug susceptibility (MODS) assay.

Setting: A multinational study conducted between February 2011 and August 2012 in Peru, India, Moldova and South Africa.

Design: In the first phase, breakpoints for the fluoroquinolones and injectable second-line drugs (n = 58) were determined. In the second phase, MODS second-line drug susceptibility testing (DST) as an indirect test was compared to MGIT™ DST (n = 89). In the third (n = 30) and fourth (n = 156) phases, we determined the reproducibility and concordance of MODS second-line DST directly from sputum.

Results: Breakpoints for MFX (0.5 μg/ml), OFX (1 μg/ml), AMK (2 μg/ml), KM (5 μg/ml) and CPM (2.5 μg/ml) were determined. In all phases, MODS results were highly concordant with MGIT DST. The few discrepancies suggest that the MODS breakpoint concentrations for some drugs may be too low.

Conclusion: MODS second-line DST yielded comparable results to MGIT second-line DST, and is thus a promising alternative. Further studies are needed to confirm the accuracy of the drug breakpoints and the reliability of MODS second-line DST as a direct test.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Amikacin / therapeutic use
  • Antitubercular Agents / therapeutic use*
  • Capreomycin / therapeutic use
  • Drug Resistance, Multiple, Bacterial*
  • Fluoroquinolones / therapeutic use
  • Humans
  • India
  • Kanamycin / therapeutic use
  • Microbial Sensitivity Tests / methods*
  • Microscopy*
  • Moldova
  • Moxifloxacin
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Ofloxacin / therapeutic use
  • Peru
  • Predictive Value of Tests
  • Reproducibility of Results
  • South Africa
  • Sputum / microbiology
  • Tuberculosis, Multidrug-Resistant / diagnosis*
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Pulmonary / diagnosis*
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents
  • Fluoroquinolones
  • Capreomycin
  • Kanamycin
  • Amikacin
  • Ofloxacin
  • Moxifloxacin